Medicus Pharma (NASDAQ:MDCX) Releases Earnings Results, Misses Expectations By $4.96 EPS

Medicus Pharma (NASDAQ:MDCX) released its earnings results on Friday. The company reported ($11.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.68) by ($4.96), FiscalAI reports.

Medicus Pharma Price Performance

NASDAQ MDCX traded up $0.04 on Friday, hitting $1.87. 29,253 shares of the stock were exchanged, compared to its average volume of 97,217. The company has a market capitalization of $2.36 million, a PE ratio of -0.02 and a beta of 0.80. The business’s fifty day moving average is $6.14 and its 200 day moving average is $21.72. Medicus Pharma has a 52 week low of $1.70 and a 52 week high of $127.50.

Wall Street Analyst Weigh In

MDCX has been the subject of several recent research reports. Alliance Global Partners reissued a “buy” rating on shares of Medicus Pharma in a research report on Monday, September 14th. Wall Street Zen raised Medicus Pharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 31st. Finally, Weiss Ratings raised Medicus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Medicus Pharma presently has an average rating of “Moderate Buy” and an average target price of $450.00.

About Medicus Pharma

Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes.

Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.